An Emerging Nanomedicine Leader
Spago Nanomedical is a Swedish nanomedicine company in clinical development phase with a proprietary platform of polymeric materials that targets more precise diagnosis and treatment of life-threatening and debilitating diseases.
The development projects, SpagoPix and Tumorad® have unique properties with potential to significantly improve healthcare for the benefit of patients. In SpagoPix, initial clinical data indicate that the candidate drug SN132D provides imaging with good contrast of breast cancer and the pancreas, without compromising safety. With better diagnostics, the chances of successful and cost-efficient treatment of patients improve. In Tumorad®, preclinical findings indicate that the candidate drug SN201 accumulates in aggressive tumors and delays tumor growth at clinically useful doses. This opens up a wide range of applications for SN201 in the treatment of various forms of cancer.